Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific...
Main Authors: | Ghosn, Marwan, Dagher, Alain, El-Karak, Fadi |
---|---|
Format: | Online |
Language: | English |
Published: |
Editorial Department of Journal of Biomedical Research
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585438/ |
Similar Items
-
Sequencing of Cabazitaxel in Metastatic Castrate-Resistant Prostate Cancer: A Case Report
by: Colbourn, Donald
Published: (2012) -
Complete Radiologic Response in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel
by: Mofid, Bahram, et al.
Published: (2015) -
The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
by: Fosså, S. D., et al.
Published: (1992) -
Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
by: Calcagno, Fabien, et al.
Published: (2012) -
Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
by: Tsao, Che-Kai, et al.
Published: (2011)